JOYCE HISAE YAMAMOTO

(Fonte: Lattes)
Índice h a partir de 2011
12
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 10 de 58
  • conferenceObject
    Comparative analysis of different treatment schedules in the course of Vogt-Koyanagi-Harada disease (VKHD)
    (2019) YAMAMOTO, Joyce H.; LAVEZZO, Marcelo Mendes; SAKATA, Viviane Mayumi; RODRIGUEZ, Ever Ernesto Caso; KANENOBU, Cintia; ABDALLAH, Smairah Frutuoso; MORITA, Celso; OYAMADA, Maria Kiyoko; HIRATA, Carlos Eduardo
  • article 1 Citação(ões) na Scopus
    Vogt-Koyanagi-Harada disease after discontinuation of systemic treatment
    (2022) SOUTO, Fernanda M. S.; LAVEZZO, Marcelo M.; OYAMADA, Maria K.; YAMAMOTO, Joyce H.
  • conferenceObject
    Vogt-Koyanagi-Harada disease (VKHD) after systemic treatment discontinuation
    (2021) SOUTO, Fernanda Maria Silveira; MISSAKA, Ruy Felippe Brito Goncalves; LAVEZZO, Marcelo Mendes; NOBREGA, Priscilla Figueiredo Campos; SAKATA, Viviane Mayumi; OYAMADA, Maria Kiyoko; HIRATA, Carlos Eduardo; YAMAMOTO, Joyce H.
  • conferenceObject
    Subclinical signs persistence in Vogt-Koyanagi-Harada disease (VKHD) patients treated with early high-dose corticosteroids and immunosuppressive therapy
    (2018) TAKIUTI, J. H. Yamamoto; LAVEZZO, M. M.; SAKATA, V. M.; KANENOBU, C.; MORITA, C.; OYAMADA, M. K.; HIRATA, C. E.
  • conferenceObject
    Association between visual function and quality of life in patients with Vogt-Koyanagi-Harada disease
    (2018) TAKIUTI, J. H. Yamamoto; MISSAKA, R. F.; SOUTO, F. M.; MARCHIORI, B. M.; CAETANO, V. M.; TAKIUTI, J. T.; LAVEZZO, M. M.; OYAMADA, M. K.; HIRATA, C. E.
  • conferenceObject
    Retinal vasculitis (RV) in pediatric population: case series
    (2020) GIAMPIETRO, Barbara; SOUTO, Fernanda Maria Silveira; TAKIUTI, Julia Tieme; CAMPOS, Lucia Maria Arruda; HIRATA, Carlos Eduardo; YAMAMOTO, Joyce H.
  • conferenceObject
    Clinical characteristics, outcome, and management of Staphylococcus epidermidis endophthalmitis
    (2019) TANAKA, Tatiana; KATO, Juliana Mika; OLIVEIRA, Luiza Manhezi Shin de Shin de; ODA, Eduardo Ferracioli; BARBOSA, Thaisa Silveira; ROSSI, Flavia; ALMEIDA JUNIOR, Joao Nobrega; YAMAMOTO, Joyce Hisae
  • article 24 Citação(ões) na Scopus
    Indocyanine green angiography findings in patients with long-standing Vogt-Koyanagi-Harada disease: a cross-sectional study
    (2012) SILVA, Felipe T. da; HIRATA, Carlos E.; SAKATA, Viviane M.; OLIVALVES, Edilberto; PRETI, Rony; PIMENTEL, Sergio L. G.; GOMES, Andre; TAKAHASHI, Walter Y.; COSTA, Rogerio A.; YAMAMOTO, Joyce H.
    Background: To investigate indocyanine green angiography (ICGA) findings in patients with long-standing Vogt-Koyanagi-Harada (VKH) disease and their correlation with disease activity on clinical examination as well as with systemic corticosteroid therapy. Methods: Twenty-eight patients (51 eyes) with long-standing (>= 6 months from disease onset) VKH disease whose treatment was tapered based only in clinical features were prospectively included at a single center in Brazil. All patients underwent standardized clinical evaluation, which included fundus photography, fluorescein angiography and ICGA. Clinical disease activity was determined based in the Standardization in Uveitis Nomenclature Working Group. Fisher exact test and logistic regression models were used for statistical analysis. Results: Disease-related choroidal inflammation on ICGA was observed in 72.5% (31 of 51 eyes). Angiographic findings suggestive of (choroidal and/or retinal) disease activity were not observed on FA. Clinically active disease based on clinical evaluation was observed in 41.2% (21 of 51 eyes). In these 21 eyes, disease-related choroidal inflammation on ICGA was observed in 76.2% (16 of 21 eyes); in the remaining eyes (without clinical active disease) disease-related choroidal inflammation on ICGA was observed in 70.0% (21 of 30 eyes). In respect to systemic corticosteroid therapy, 10 patients (18 of 51 eyes) were under treatment with prednisone. In these 10 (18 of 51 eyes) patients, disease-related choroidal inflammation on ICGA was observed in 83.3% (15 of 18 eyes); in the remaining patients (33 of 51 eyes) disease-related choroidal inflammation on ICGA was observed in 66.7% (22 of 33 eyes). Conclusion: ICGA findings suggestive of disease-related choroidal inflammation were observed in a considerable proportion of patients with long-standing VKH disease, independent of the inflammatory status of the disease on clinical examination or current use of systemic corticosteroid. Therefore, the current study reinforces the crucial role of ICGA to assist the management and treatment of patients with long-standing VKH disease.
  • conferenceObject
    Correlation between visual function and clinical/subclinical disease activity parameters in Vogt-Koyanagi-Harada disease (VKHD).
    (2017) LAVEZZO, Marcelo Mendes; SAKATA, Viviane Mayumi; RODRIGUEZ, Ever Ernesto Caso; ABDALLAH, Smairah Frutuoso; MORITA, Celso; OYAMADA, Maria Kiyoko; HIRATA, Carlos Eduardo; YAMAMOTO, Joyce H.
  • article 2 Citação(ões) na Scopus
    Outcomes of Intravitreal Bevacizumab in Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease-A Prospective Study
    (2021) SAKATA, Viviane M.; MORITA, Celso; LAVEZZO, Marcelo M.; RODRIGUEZ, Ever E. C.; ABDALLAH, Smairah F.; PIMENTEL, Sergio L. G.; HIRATA, Carlos E.; YAMAMOTO, Joyce H.
    Purpose: To assess the effectiveness of intravitreal (IV) bevacizumab and the need for systemic immunosuppressive therapy (IMT) in choroidal neovascularization (CNV) in Vogt-Koyanagi-Harada disease (VKHD). Methods: CNV treatment consisted of three monthly IV bevacizumab injections as a loading dose; if intra/subretinal fluid (IRF) persisted, further injections were proceeded besides increment in systemic IMT. Outcome analyses at 3, 6, and 12 months were visual acuity, central foveal thickness, macular volume, IRF, and addition of IMT. Results: Seven eyes of six patients were included. Five patients (five eyes) completed a 12-month follow-up and received 12 IV bevacizumab injections. At the 12-month follow-up, visual acuity improved in four out of five eyes (p = .0568); all eyes had decreased macular volume (p = .0431) but they still had persistent IRF; and all cases needed IMT introduction/increment. Conclusion: Intravitreal bevacizumab in association with systemic IMT was effective for CNV in VKHD. Active CNV may indicate disease of inadequate clinical control.